In this article, we will list the 5 Oversold Stocks to Buy Right Now. Please visit 8 Oversold Stocks to Buy Right Now to see the extended list and the methodology behind it.
5. Insulet Corporation (NASDAQ:PODD)
Number of Hedge Fund Holders: 55
Insulet Corporation (NASDAQ:PODD) is one of the oversold stocks to buy right now. On June 3, Insulet launched significant enhancements to its Omnipod 5 Automated Insulin Delivery/AID System in the US, featuring a new 100 mg/dL Target Glucose option. This update allows for greater personalization and improved glycemic control, enabling users to increase their time in range with fewer system interruptions during high glucose events. The rollout is currently underway, with compatible Pods already shipping to retail channels.
Expanding its commitment to user choice and system flexibility, Insulet has also integrated the Omnipod 5 with Abbott’s FreeStyle Libre 3 Plus sensor. This compatibility allows for broader sensor options and includes support for the LibreLinkup app, facilitating easier tracking for caregivers. These updates represent the most substantial algorithm advancement for the platform since its 2022 launch, reinforcing the company’s focus on reducing the daily burden of diabetes management.
Insulet Corporation (NASDAQ:PODD) plans to present further details regarding these advancements at the American Diabetes Association’s 86th Scientific Sessions in New Orleans. By offering more flexible target settings and wider sensor integration, the company aims to remove barriers to AID technology and improve outcomes for people with type 1 and type 2 diabetes. Additional international rollouts for these features are expected to follow later this year.
Insulet Corporation (NASDAQ:PODD) is a medical device company focused on developing, manufacturing, and selling insulin delivery systems for patients with diabetes.
4. Zoetis Inc. (NYSE:ZTS)
Number of Hedge Fund Holders: 57
Zoetis Inc. (NYSE:ZTS) is one of the oversold stocks to buy right now. On May 28, Zoetis received approval from the UK’s Veterinary Medicines Directorate for Lenivia (izenivetmab), a new long-acting monoclonal antibody therapy for alleviating osteoarthritis pain in dogs. Administered as a single injection, the treatment targets nerve growth factor to provide effective pain relief and improved mobility for up to three months.
Osteoarthritis is a prevalent, chronic joint disease affecting nearly 40% of dogs, significantly impacting their quality of life, mobility, and behavior. By offering a long-acting injectable option, Lenivia provides veterinary professionals with a flexible tool to support sustained comfort and manage pain as part of an individualized care plan.
This approval represents a major milestone in the company’s commitment to veterinary innovation and its expanding portfolio of monoclonal antibody therapies. Lenivia is expected to serve as a key advancement in canine pain management, helping address the significant unmet medical needs of dogs suffering from progressive joint conditions.
Zoetis Inc. (NYSE:ZTS) is a global animal health company that focuses on the discovery, development, manufacture, and commercialization of vaccines, medicines, biodevices, genetic tests, diagnostic products, and precision animal health. Its operations are divided into the United States and International segments.
3. Structure Therapeutics Inc. (NASDAQ:GPCR)
Number of Hedge Fund Holders: 58
Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the oversold stocks to buy right now. Structure Therapeutics reported positive Phase 2 results for its oral GLP-1 receptor agonist, aleniglipron, showing up to 16.3% weight loss. With favorable FDA feedback, the company is on track to initiate a Phase 3 registrational trial in Q3 2026.
The company is also advancing its oral amylin receptor agonist pipeline, with lead candidate ACCG-2671 expected to enter multiple ascending dose studies in Q3 and a second candidate, ACCG-3535, beginning clinical trials in Q4. These programs aim to provide accessible oral small-molecule treatments for metabolic diseases.
Financially, Structure Therapeutics Inc. (NASDAQ:GPCR) holds $1.5 billion in cash, providing a runway through 2028 to support its clinical programs. Detailed updates on its aleniglipron and amylin portfolios are scheduled for presentation at the American Diabetes Association’s scientific sessions this June.
Structure Therapeutics Inc. (NASDAQ:GPCR) is involved in the development and marketing of novel oral small molecule therapies for the treatment of several chronic diseases with unmet medical needs.
2. Roblox Corporation (NYSE:RBLX)
Number of Hedge Fund Holders: 66
Roblox Corporation (NYSE:RBLX) is one of the oversold stocks to buy right now. On May 19, Roblox Corporation authorized its first-ever share repurchase program, allowing the company to buy back up to $3 billion of its common stock, to acquire up to $1 billion over the next twelve months. The initiative is intended to partially offset dilution from employee equity grants while maintaining the company’s financial flexibility to pursue strategic growth.
The program allows for repurchases through various methods, including open market transactions and privately negotiated deals. There is no fixed expiration date for the authorization, and management retains full discretion regarding the timing, price, and volume of shares bought back based on prevailing market conditions and corporate requirements.
CFO Naveen Chopra emphasized that while investing in innovation and growth remains the company’s primary focus, the strength of its balance sheet and free cash flow generation enables this capital allocation strategy. The announcement reflects management’s confidence in Roblox Corporation’s (NYSE:RBLX) long-term business trajectory and its commitment to reducing shareholder dilution.
Roblox Corporation (NYSE:RBLX) provides online gaming services through its platforms: Roblox Client, Roblox Studio, and Roblox Cloud. The company is based in San Mateo, California and was founded in March 2004 by Erik Cassel and David B. Baszucki.
1. Boston Scientific Corporation (NYSE:BSX)
Number of Hedge Fund Holders: 106
Boston Scientific Corporation (NYSE:BSX) is one of the oversold stocks to buy right now. On May 18, Boston Scientific entered into an accelerated share repurchase/ASR agreement with JPMorgan Chase Bank to buy back $2 billion of its common stock, part of a previously authorized $5 billion program. The company will immediately receive approximately 30.4 million shares, representing 80% of the repurchase value based on the May 15 closing price. The final number of shares will be determined upon completion of the agreement by June 30.
This transaction leaves $3 billion remaining under the company’s total share repurchase authorization. Boston Scientific noted that the ASR is expected to be accretive to its 2026 adjusted earnings per share by $0.02, effectively improving the financial guidance it previously issued in April.
The ASR serves as a key component of Boston Scientific Corporation’s (NYSE:BSX) capital allocation strategy. By using its financial position to reduce share count, the company aims to deliver increased value to shareholders while maintaining resources for its ongoing operational and strategic goals.
Boston Scientific Corporation (NYSE:BSX) is a healthcare company, incorporated in 1979, that specializes in medical devices for interventional medical specialties. The company’s segments include MedSurg and Cardiovascular.
While we acknowledge the potential of BSX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BSX and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Best Low Risk Stocks to Buy in 2026 and 12 Best High Short Interest Stocks With Highest Upside Potential.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
